Last updated on August 2019

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated


Brief description of study

The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor blockers [ARB].

Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine Ratio [UACR].

Clinical Study Identifier: NCT03165240

Find a site near you

Start Over

Inamed GmbH

Gauting, Germany
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

HOP Nord La nnec

Saint-Herblain, France
  Connect »

D & R s.r.o.

Kosice, Slovakia
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Baltic Med,LLC Clinic BaltMed Ozerki

St. Petersburg, Russian Federation
  Connect »

Hospital de Bellvitge

L'Hospitalet de Llobregat, Spain
  Connect »

Hammersmith Hospital

London, United Kingdom
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Res.Inst.-Compl.Iss.Cardi.Dis.

Kemerovo, Russian Federation
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Yaroslavl Regional Clin. Hospital

Yaroslavl, Russian Federation
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »

Glasgow Royal Infirmary

Glasgow, United Kingdom
  Connect »

Bispebjerg Hospital

København NV, Denmark
  Connect »